UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
||
(Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbols |
Name of each exchange on which registered | ||
Item 8.01 | Other Events |
As previously disclosed, at a special meeting of stockholders on July 11, 2023 (the “Special Meeting”), the stockholders of Alpha Healthcare Acquisition Corp. III, a Delaware corporation (“ALPA” or the “Company”), approved the merger and other transactions contemplated by that certain Business Combination Agreement, dated as of January 4, 2023, among ALPA, Candy Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of ALPA (“Merger Sub”), and Carmell Therapeutics Corporation, a Delaware corporation (“Carmell”), pursuant to which Merger Sub will merge with and into Carmell, with Carmell surviving the merger as a wholly-owned subsidiary of ALPA (the “Combined Company” or “New Carmell”) (the “Business Combination”).
In connection with the Special Meeting, holders of 12,586,223 shares of Class A common stock of ALPA exercised redemption rights. The Company has prepared a preliminary calculation of its pro forma balance sheet as of March 31, 2023, giving effect to such redemption, as well as the previously announced forward purchase agreement and related transactions entered into on July 9, 2023. Such pro forma balance sheet reflects pro forma stockholders’ equity of approximately $16.1 million.
The Company expects the Business Combination to close during the morning of Friday, July 14, 2023 and the shares of New Carmell to commence trading on the Nasdaq Capital Market during the morning of Monday, July 17, 2023. The Company will file a Current Report on Form 8-K within four business days following the closing of the Business Combination containing a full set of pro forma financial statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf by the undersigned hereunto duly authorized.
Date: July 14, 2023 | ALPHA HEALTHCARE ACQUISITION CORP. III | |||||
By: | /s/ Rajiv Shukla | |||||
Rajiv Shukla | ||||||
Chief Executive Officer |